Pharmaceuticals, Biotechnology and Life Sciences
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical…
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory…
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY,…
Ohio-born cannabis brand brings personal story, community focus, and premium products to Silver Drive locationCOLUMBUS, Ohio, Oct. 09, 2025 (GLOBE…
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct. 09,…
Results from the study of oral gildeuretinol in moderate Stargardt disease to be presented as late-breaker during Retina Subspecialty DayCAMBRIDGE,…
Partnership to Enable U.S. Access to Toro’s Novel Neurovascular Catheter Portfolio Pending Regulatory Approval Toro Hero Toro Neurovascular’s catheter technology,…
ST. LOUIS, Oct. 09, 2025 (GLOBE NEWSWIRE) — Following 10+ years of service to Cushing’s syndrome patients, Optime Care, a…
BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel…
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing…